A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI

• Published in: EBioMedicine 2021-01, Vol.63, p.103163-103163, Article 103163
• Main Authors: Li, Lin, Shiradkar, Rakesh, Leo, Patrick, Algohary, Ahmad, Fu, Pingfu, Tirumani, Sree Harsha, Mahran, Amr, Buzzy, Christina, Obmann, Verena C, Mansoori, Bahar, El-Fahmawi, Ayah, Shahait, Mohammed, Tewari, Ashutosh, Magi-Galluzzi, Cristina, Lee, David, Lal, Priti, Ponsky, Lee, Klein, Eric, Purysko, Andrei S., Madabhushi, Anant
• Format: Article
• Language: English
• Subjects: Adverse pathology; Biochemical recurrence; MRI; Prognosis; Prostate cancer; Radiomic; Research Paper
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2020.103163

We developed and validated an integrated radiomic-clinicopathologic nomogram (RadClip) for post-surgical biochemical recurrence free survival (bRFS) and adverse pathology (AP) prediction in men with prostate cancer (PCa). RadClip was further compared against extant prognostics tools like CAPRA and Decipher. A retrospective study of 198 patients with PCa from four institutions who underwent pre-operative 3 Tesla MRI followed by radical prostatectomy, between 2009 and 2017 with a median 35-month follow-up was performed. Radiomic features were extracted from prostate cancer regions on bi-parametric magnetic resonance imaging (bpMRI). Cox Proportional-Hazards (CPH) model warped with minimum redundancy maximum relevance (MRMR) feature selection was employed to select bpMRI radiomic features for bRFS prediction in the training set (D1, N = 71). In addition, a bpMRI radiomic risk score (RadS) and associated nomogram, RadClip, were constructed in D1 and then compared against the Decipher, pre-operative (CAPRA), and post-operative (CAPRA-S) nomograms for bRFS and AP prediction in the testing set (D2, N = 127). “RadClip yielded a higher C-index (0.77, 95% CI 0.65-0.88) compared to CAPRA (0.68, 95% CI 0.57-0.8) and Decipher (0.51, 95% CI 0.33-0.69) and was found to be comparable to CAPRA-S (0.75, 95% CI 0.65-0.85). RadClip resulted in a higher AUC (0.71, 95% CI 0.62-0.81) for predicting AP compared to Decipher (0.66, 95% CI 0.56-0.77) and CAPRA (0.69, 95% CI 0.59-0.79).” RadClip was more prognostic of bRFS and AP compared to Decipher and CAPRA. It could help pre-operatively identify PCa patients at low risk of biochemical recurrence and AP and who therefore might defer additional therapy. The National Institutes of Health, the U.S. Department of Veterans Affairs, and the Department of Defense.